Laryngeal CancerSymptoms, Doctors, Treatments, Advances & More
Laryngeal Cancer Overview
Learn About Laryngeal Cancer
Otolaryngology - Head & Neck Surgery At Cherry Hill
Joseph Curry is an Otolaryngologist and a General Surgeon practicing medicine in Cherry Hill, New Jersey. Dr. Curry is rated as an Elite provider by MediFind in the treatment of Laryngeal Cancer. He is also highly rated in 46 other conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Duct Stones, Laryngeal Cancer, Laryngectomy, and Gastrostomy. Dr. Curry is board certified in Otolaryngology. Dr. Curry is currently accepting new patients.
UT MD Anderson Cancer Center
Mark Zafereo is an Otolaryngologist practicing medicine in Houston, Texas. Dr. Zafereo is rated as an Elite provider by MediFind in the treatment of Laryngeal Cancer. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Anaplastic Thyroid Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Thyroidectomy, and Laryngectomy.
Penn Otorhinolaryngology - Head And Neck Surgery Perelman
Gregory Weinstein is an Otolaryngologist practicing medicine in Philadelphia, Pennsylvania. Dr. Weinstein is rated as an Elite provider by MediFind in the treatment of Laryngeal Cancer. He is also highly rated in 37 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Salivary Gland Tumors, Laryngectomy, and Gastrostomy. Dr. Weinstein is board certified in Otolaryngology, 1990. Dr. Weinstein is currently accepting new patients.
Summary: This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cisplatin for high risk patients, for the treatment of patients with PD-L1 positive head and neck squamous cell carcinoma that has come back and spread to nearby tiss...
Summary: This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1140 is a monoclonal antibo...
